Focus on Myeloid Malignancies (Volume 7, Issue 6.1)

May 2021 Special Edition

Volume 7, Issue 6.1

This supplement explores JAK inhibitors for myelofibrosis, cellular therapies for myeloid malignancies, and more.

Table of Contents

May 2021 Special Edition

Four of a Kind?

Saturday, May 1st, 2021
Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis. For many of his patients with myelofibrosis, ruxolitinib has been...

Cellular Therapies Hold Promise in Myeloid Malignancies

Saturday, May 1st, 2021
There is hope that these therapies will improve outcomes, but development is still in early stages.  A recent spate of approvals of targeted treatments, such...

May 2021 Special Edition

Next-Generation Karyotyping Outperforms Conventional Cytogenetics for Prognostication of AML

Saturday, May 1st, 2021
Compared with conventional cytogenetic analysis (CCA), next generation sequencing (NGS)–based karyotyping offered greater insight into the prognosis of patients with intensively treated acute myeloid...

Universal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML

Saturday, May 1st, 2021
Initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany, suggest that UniCAR, a universal,...